580 related articles for article (PubMed ID: 18486759)
21. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA
Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392
[TBL] [Abstract][Full Text] [Related]
23. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
24. [Prokaryotic expression, purification of HSP65-MUC1 VNTR2 fusion protein and primary research on its tumoricidal effect].
Zheng YL; Jiang H; Wang XL; Jiang YQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1014-6. PubMed ID: 17988580
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA.
Mushenkova N; Moiseeva E; Chaadaeva A; Den Otter W; Svirshchevskaya E
Anticancer Res; 2005; 25(6B):3893-8. PubMed ID: 16309176
[TBL] [Abstract][Full Text] [Related]
26. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.
Chu Y; Xia M; Lin Y; Li A; Wang Y; Liu R; Xiong S
Cancer Gene Ther; 2006 May; 13(5):510-9. PubMed ID: 16341143
[TBL] [Abstract][Full Text] [Related]
27. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
29. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
[TBL] [Abstract][Full Text] [Related]
30. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.
Tang CK; Sheng KC; Pouniotis D; Esparon S; Son HY; Kim CW; Pietersz GA; Apostolopoulos V
Vaccine; 2008 Jul; 26(31):3827-34. PubMed ID: 18550230
[TBL] [Abstract][Full Text] [Related]
31. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2.
Rittich S; Duskova M; Mackova J; Pokorna D; Jinoch P; Smahel M
Oncol Rep; 2005 Feb; 13(2):311-7. PubMed ID: 15643517
[TBL] [Abstract][Full Text] [Related]
32. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.
Acres RB; Hareuveni M; Balloul JM; Kieny MP
J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):136-43. PubMed ID: 8280702
[TBL] [Abstract][Full Text] [Related]
33. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
34. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
36. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
39. Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant.
Ruan J; Duan Y; Li F; Wang Z
Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):71-78. PubMed ID: 27562635
[TBL] [Abstract][Full Text] [Related]
40. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.
Lewēn S; Zhou H; Hu HD; Cheng T; Markowitz D; Reisfeld RA; Xiang R; Luo Y
Cancer Immunol Immunother; 2008 Apr; 57(4):507-15. PubMed ID: 17786443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
